Condition: Hodgkin Lymphoma · Sponsor: Veronika Bachanova
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
This description comes directly from the study's public registry record.
Veronika Bachanova · 612-625-5469 · bach0173@umn.edu
Ahran Lee · 317-634-5842 · alee@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| University of Illinois Cancer Center | Chicago, Illinois, United States | Completed |
| Indiana Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Withdrawn |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Active Not Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| University of Wisconsin | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03681561